S
Susan L. Greenspan
Researcher at University of Pittsburgh
Publications - 275
Citations - 20761
Susan L. Greenspan is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 76, co-authored 265 publications receiving 19032 citations. Previous affiliations of Susan L. Greenspan include Beth Israel Deaconess Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Dennis M. Black,Susan L. Greenspan,Kristine E. Ensrud,Lisa Palermo,Joan McGowan,Thomas Lang,P. Garnero,Mary L. Bouxsein,John P. Bilezikian,Clifford J. Rosen +9 more
TL;DR: Changes in the volumetric density of trabecular bone, the cortical volume at the hip, and levels of markers of bone turnover suggest that the concurrent use of alendronate may reduce the anabolic effects of parathyroid hormone.
Journal ArticleDOI
Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly.
TL;DR: It is concluded that among elderly fallers--in most of whom hip BMD is already less than the fracture threshold--fall characteristics and body habitus are important risk factors for hip fracture and touch on a domain entirely missed by knowledge of BMD.
Journal ArticleDOI
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Dennis M. Black,John P. Bilezikian,Kristine E. Ensrud,Susan L. Greenspan,L. Palermo,Trisha F. Hue,Thomas Lang,Joan McGowan,Clifford J. Rosen +8 more
TL;DR: After one year of parathyroid hormone (1-84), densitometric gains appear to be maintained or increased with alendronate but lost if parathyro hormone is not followed by an antiresorptive agent, which has clinical implications for therapeutic choices after the discontinuation of par Kathyroid hormone.
Journal ArticleDOI
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Robert A. Adler,Ghada El-Hajj Fuleihan,Douglas C. Bauer,Pauline M. Camacho,Bart L. Clarke,Gregory A. Clines,Juliet E. Compston,Matthew T. Drake,Beatrice J. Edwards,Murray J. Favus,Susan L. Greenspan,Ross E. McKinney,Robert J. Pignolo,Deborah E. Sellmeyer +13 more
TL;DR: The ASBMR Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered, and in women at high risk, older women, those with a low hip T-score or high fracture risk score, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be consideration.
Journal ArticleDOI
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
Marc C. Hochberg,Susan L. Greenspan,Richard D. Wasnich,Paul Miller,Desmond E. Thompson,Philip D. Ross +5 more
TL;DR: A meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis demonstrated that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures.